Central Coordinating Site for the Polycystic Kidney Disease Research Core Centers (U24 Clinical Trial Not Allowed)
ID: 355998Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355998

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-015.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity for the establishment of a Central Coordinating Site (CCS) for the Polycystic Kidney Disease (PKD) Research Core Centers, under the announcement RFA-DK-25-015. The CCS will collaborate with four Research Translation Core Centers to enhance understanding and management of PKD, providing essential administrative support, facilitating data sharing, and promoting outreach efforts, including an annual scientific symposium. This initiative emphasizes the importance of diverse perspectives in scientific innovation and aims to optimize resources for pioneering PKD research, with approximately $1.1 million available for one award, and an annual budget of about $350,000. Interested applicants must adhere to submission guidelines via Grants.gov, with a closing date for applications set for November 14, 2024. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DK-25-015-Full-Announcement.html
    RFA-DK-25-015.html
    The National Institutes of Health (NIH) is releasing a funding opportunity for a Central Coordinating Site for the Polycystic Kidney Disease Research Core Centers, denoted as RFA-DK-25-015. This initiative aims to enhance understanding and management of polycystic kidney disease (PKD) through improved collaboration within the PKD Research Resource Consortium (PKD RRC). The successful applicant will facilitate administrative support, manage data sharing, and drive outreach efforts including an annual scientific symposium. Furthermore, a focus on diversity through the required Plan for Enhancing Diverse Perspectives (PEDP) underlines the importance of varied viewpoints in scientific innovation. Funding is approximately $1.1 million for one award, with an annual budget of about $350,000, emphasizing innovative pilot projects in PKD research. Applications are to adhere strictly to submission guidelines via Grants.gov, with a range of eligibility criteria aimed at fostering participation from diverse organizational types. The central goal is to optimize resources and data sharing to promote pioneering PKD research, ultimately broadening participation from diverse scientific backgrounds while addressing barriers to research entry.
    Similar Opportunities
    Continuation of the NIDDK Hematology Central Coordinating Center (U24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the continuation of the NIDDK Hematology Central Coordinating Center (HCCC) through a cooperative agreement, aimed at enhancing collaboration among up to five Cooperative Centers of Excellence in Hematology. The HCCC will provide essential administrative and communication support, manage a Pilot and Feasibility Program, and promote research addressing nonmalignant hematologic diseases and normal hematopoiesis. This initiative is crucial for invigorating the field of hematology, fostering partnerships, and ensuring diverse perspectives in research teams. Interested applicants can find more information and apply by March 18, 2025, with an estimated funding amount of up to $1,000,000. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-023.html.
    NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is offering a funding opportunity for high-risk multi-center clinical study implementation planning via Cooperative Agreements (U34). This initiative aims to support the early peer review of proposed clinical studies, assess study designs, and develop essential documentation, including operational manuals, focusing on diseases relevant to NIDDK's mission. The program emphasizes health equity and inclusivity, requiring a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Interested applicants can apply for up to $225,000 per year for a maximum of two years, with the application submission period opening on September 9, 2024, and the closing date set for June 10, 2027. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting investigator-initiated, high-risk clinical trials that involve multiple clinical centers. Applicants must propose hypothesis-driven studies that focus on diseases relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with an emphasis on enhancing diverse perspectives in research. This funding opportunity is crucial for advancing therapeutic studies that can significantly improve clinical practices and public health outcomes. Interested applicants should note that the application period opens on January 5, 2024, with a closing date of November 5, 2026, and are encouraged to consult with NIDDK staff prior to submission. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Funding Opportunity Announcement (FOA) for Cancer Center Support Grants (CCSGs) aimed at supporting NCI-designated Cancer Centers under the P30 activity code. These grants are designed to foster excellence in cancer research by integrating diverse research activities and enhancing collaboration among institutions, with eligible applicants including various educational and community organizations. The CCSGs emphasize a transdisciplinary approach to cancer research, with funding amounts of up to $1.2 million for Basic Cancer Centers and $1.4 million for Clinical Cancer Centers per year, potentially extending over five years based on merit. Interested parties can find more information and application details at the NIH website, and inquiries can be directed to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV. The application deadline is set for October 12, 2121.
    NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01), aimed at supporting high-risk observational studies related to diabetes, digestive, kidney, and metabolic diseases. Applicants must complete all planning activities prior to submission, as these cannot be included in the U01 application, and a Plan for Enhancing Diverse Perspectives (PEDP) is mandatory for consideration. This funding opportunity is crucial for advancing clinical research and addressing health disparities, particularly by encouraging collaboration with underrepresented communities. Interested applicants should note that the application deadline is February 5, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the establishment or renewal of Alzheimer's Disease Research Centers (ADRCs) through Grant Opportunity RFA-AG-24-001. This initiative aims to foster multidisciplinary collaboration and resource sharing among institutions dedicated to researching Alzheimer's Disease (AD) and related dementias (ADRD), with a focus on enhancing diverse perspectives in research. The program will provide a total of $32 million for seven awards in FY 2024, increasing to $65 million for 14 awards in both FY 2025 and FY 2026, with a maximum project budget of $2.925 million per year and a project period of up to five years. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov, with the application deadline set for September 26, 2025.
    NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDDK Catalyst Award (DP1 Clinical Trial Not Allowed) to support pioneering biomedical research focused on critical scientific challenges related to diabetes, digestive diseases, and kidney diseases. This grant aims to fund individual scientists proposing innovative and high-impact studies that diverge from their existing research, encouraging bold ideas and unconventional hypotheses within the domains of the Division of Diabetes, Endocrinology and Metabolic Diseases and the Division of Digestive Diseases and Nutrition. The award has a budget ceiling of $500,000 per year for a maximum project period of five years, with a total funding commitment of $4.8 million for FY 2026 to support up to six awards. Interested applicants must adhere to NIH registration requirements and submit their proposals by July 18, 2025, with further inquiries directed to grantsinfo@nih.gov.
    Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the development of a Clinical Coordinating Center (CCC) to support multi-site investigator-initiated clinical trials under the UG3/UH3 activity codes. This initiative aims to foster innovative trial designs relevant to the National Heart, Lung, and Blood Institute's (NHLBI) research mission, requiring comprehensive project plans that address participant recruitment, milestone achievements, and strategies for enhancing community engagement and diversity. The funding mechanism is bi-phasic and necessitates simultaneous applications for both a CCC and a collaborating Data Coordinating Center (DCC), emphasizing strong project management and a commitment to minimizing health disparities. Interested applicants must submit their proposals by September 11, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries. More details can be found in the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-192.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for Precision Medicine for Type 1 Diabetic Nephropathy (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for a cooperative agreement aimed at advancing research on Type 1 Diabetic nephropathy (T1D). This initiative seeks applications from Recruitment Sites (RS) to enroll adult and pediatric patients with T1D, particularly those at high risk for diabetic nephropathy, into a longitudinal cohort study, which will include protocol-based kidney biopsies. The research will leverage existing resources from the Kidney Precision Medicine Project (KPMP) to create a Kidney Tissue Atlas, identify disease subgroups, and explore novel therapeutic targets. The estimated total program funding for this opportunity is $1.3 million, with the NOFO expected to be published in fall 2024 and applications due in late fall 2024. Interested applicants are encouraged to reach out to the NIDDK contacts provided in the announcement for further information.
    Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for Cancer Center Support Grants (CCSGs) aimed at supporting NCI-designated Cancer Centers through the P30 funding mechanism. This initiative seeks to enhance collaborative cancer research across various domains, including basic laboratory, clinical, and prevention research, with eligibility extending to Comprehensive Cancer Centers, Clinical Cancer Centers, and Basic Cancer Centers that demonstrate significant research capabilities and community engagement. The funding, which has an award ceiling of $1.5 million, is intended to foster transdisciplinary research collaboration, create shared resources, and ensure equitable participation in cancer research across diverse populations. Interested applicants must submit their proposals by January 7, 2026, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further information.